Peptides for Immune Support

Immune Support Peptide Therapy Overview

Peptide immunotherapy targets immune system function at the cellular level. Thymosin Alpha-1 enhances T-cell maturation and has been approved in over 30 countries for hepatitis and as an immune adjuvant. LL-37 (Cathelicidin) provides direct antimicrobial defense and immune signaling. Both are on the RFK reclassification list.

• Enhanced T-cell function and maturation
• Direct antimicrobial defense
• Reduced autoimmune inflammation
• Support for chronic infection management
• Immune system rebalancing (not just boosting)

How Immune Support Peptides Work

Immune peptides work through fundamentally different mechanisms than traditional immune "boosters." Thymosin Alpha-1 is a 28-amino acid peptide naturally produced by the thymus gland. It promotes the maturation and differentiation of T-cells (the adaptive immune system's primary fighters), enhances dendritic cell function (which presents threats to T-cells), and increases natural killer (NK) cell activity. Critically, it's an immune modulator, not just an immune stimulant — it upregulates underactive immune responses while tempering overactive ones, which is why it's used in both immunodeficiency and autoimmune conditions. LL-37 (Cathelicidin) is a human antimicrobial peptide that directly kills bacteria, viruses, and fungi by disrupting their cell membranes. It also activates toll-like receptors (TLRs) on immune cells, triggering innate immune cascades. KPV is a potent anti-inflammatory tripeptide that inhibits NF-kB, reducing the chronic inflammation that underlies most immune dysfunction.

Peptides Used for Immune Support

Who Is Immune Support Peptide Therapy For?

Immune peptide therapy is appropriate for patients with recurrent infections, chronic viral conditions (EBV, Lyme, hepatitis), post-COVID immune dysfunction, diagnosed immunodeficiency, or autoimmune conditions requiring immune modulation rather than broad suppression. Also used prophylactically by longevity-focused patients wanting to maintain robust immune function as the thymus involutes with age. Thymosin Alpha-1 has been used as an adjunct in cancer immunotherapy. Not appropriate for patients on immunosuppressive therapy (organ transplant recipients) without specialist oversight, or those with undiagnosed immune conditions — get a workup first.

Immune peptide protocols are tailored to the patient's condition. Thymosin Alpha-1 is typically dosed at 1.6mg SC, 2–3x/week for immune deficiency, or 1.6mg daily during acute illness (Lyme, chronic viral infections). Treatment courses run 3–6 months with lab monitoring. LL-37 is dosed at 50–100mcg/day SC for 2–4 weeks during active infection or SIBO, then discontinued. KPV is administered orally (200–500mcg capsules) or SC for anti-inflammatory support. For autoimmune patients, Thymosin Alpha-1 can be combined with low-dose naltrexone (LDN) for synergistic immune modulation. Comprehensive immune labs at baseline and every 8 weeks: CD4/CD8 ratio, NK cell count and function, immunoglobulins (IgG, IgA, IgM), inflammatory markers (hsCRP, IL-6, TNF-alpha), and infection-specific tests (EBV, Lyme panels) as indicated.

Immune Support Peptide News

News aggregated via Google News. Inclusion does not imply endorsement.

Immune Support Guides & Resources

Immune Support Peptide FAQs